Skip to main content

LEVAQUIN


Product Liability Lawyer representing plaintiffs nationwide in Pharmaceutical Litigation and drug injury cases
Nationwide Success

Antibiotic Injury Lawsuits

investigating levaquin injury claims

Use of antibiotics like Levaquin (levofloxacin) appears to be associated with an increased risk for the severe aortic events, even years after exposure. Recent studies, published by the American Medical Association suggest the use of fluoroquinolone antibiotics, like Levaquin, may be associated with an increased risk for life-threatening aortic aneurysms and aortic dissections.

The researchers note that the incidence of aortic dissection and aortic aneurysm in America has risen over the last several decades, with an estimated 15,000 Americans dying each year. The studies, published in the Pharmaceutical Journal, say they have identified a “novel association” between Levaquin use and emergency aortic issues.

Aortic dissection occurs when the walls of the aorta break down, allowing blood to seep into the layers of tissue. The condition may lead to serious complications like stroke, heart attack or paralysis. In some scenarios, patients only have a 50 percent chance of survival.

Joe Lyon is a highly-rated Levaquin Lawyer and pharmaceutical injury attorney, representing plaintiffs nationwide in a wide variety of wrongful death and Levaquin injury claims.  


Levaquin Injury & Black Box Warning


Fluoroquinolone antibiotics are useful in treating various infections; however, they are also linked to dangerous side effects like permanent nerve damage and aortic aneurysms and dissections.

Newer research builds on prior studies that concerned health professionals as far back as 2008, when the U.S. Food and Drug Administration (FDA) announced that it would require a boxed warning about the risk of tendinitis and tendon rupture on fluoroquinolone packaging. Cipro, Levaquin, AveloxNoroxin were the specific drugs listed in the FDA warning.

In 2013, the FDA went one step further and issued an additional warning about permanent nerve damage as a possible side effect of Levaquin and other drugs of the same class. The agency said the effects could be “disabling” and recommended their use be restricted.

The more recent studies, published by the American College of Cardiology, are consistent with past findings that the drugs aggravate aortic aneurysm and dissection in the same way they damages the collagen in tendons. The research explained: “Not only is tendon composed of collagen, collagen is also a major extracellular matrix component of the aortic wall.”

CONTACT THE LYON FIRM TODAY

Please complete the form below for a FREE consultation.

  • This field is for validation purposes and should be left unchanged.

ABOUT THE LYON FIRM

Joseph Lyon has 17 years of experience representing individuals in complex litigation matters. He has represented individuals in every state against many of the largest companies in the world.

The Firm focuses on single-event civil cases and class actions involving corporate neglect & fraud, toxic exposure, product defects & recalls, medical malpractice, and invasion of privacy.

NO COST UNLESS WE WIN

The Firm offers contingency fees, advancing all costs of the litigation, and accepting the full financial risk, allowing our clients full access to the legal system while reducing the financial stress while they focus on their healthcare and financial needs.


Antibiotic Injury & Levaquin Lawsuits


Use of fluoroquinolones like Levaquin has been associated with increased risk for drug injury like aortic aneurysm or dissection, and also several other disorders including the following:

•    Achilles tendon rupture
•    Tendinopathy
•    Retinal detachment
•    Nerve damage
•    Convulsions
•    Hypersensitivity
•    Hallucinations
•    Depression and anxiety
•    Vision problems
•    Adverse Cardiac Events
•    Fatigue
•    Muscle aches
•    Joint pain


An FDA adverse reaction database involving Levaquin shows tens of thousands of complaints and Levaquin injury cases from 1997 to present date. Contact an Ohio Levaquin Lawyer to discuss your specific Levaquin injury. 


Levaquin Injury Risk


Any patient taking like Levaquin could be at risk of developing cardiac issues like aortic dissection. Evidence suggests the duration of drug therapy may be a factor, but adverse side effects have been reported even after the first dose.

In 2015, a study of 1.7 million patients, published in the BMJ Open medical journal, found that within 30 days of finishing a course of treatment, patients who received fluoroquinolones like Levaquin were more than two times more likely to experience aortic aneurysm than other patients.


Common Uses for Levaquin


Levaquin (levofloxacin) is a broad spectrum antibiotic commonly used to treat a wide variety of bacterial infections, including the following:

•    Skin infection
•    Sinus infection
•    Prostate infection
•    Kidney infection
•    Bladder infection
•    Anthrax exposure
•    Bronchitis


Symptoms of Aortic Dissection


Research from the University of Toronto, which found that fluoroquinolone use is associated with an increased risk of aortic aneurysm, suggests more prudent use of the antibiotics could avoid countless aortic aneurysms.

The research team concluded: “Our data suggest that fluoroquinolone prescriptions can contribute acutely to aneurysm progression and rupture.”
It is essential that aortic aneurysms and dissections are diagnosed quickly. Please seek medical attention if you experience related symptoms such as the following:

•    Severe pain in chest or back
•    A sudden increase or decrease in blood pressure
•    Shortness of breath
•    Sudden difficulty speaking
•    Loss of vision
•    Weakness on one side of the body


More than 26 million Americans receive a prescription for a fluoroquinolone antibiotic like Levaquin, Cipro, Noroxin or Avelox each year. Public health officials note that the increased use of the drugs makes them a significant concern.

Although fluoroquinolone like Levaquin are effective treatments for common bacterial infections, alternate drugs or shorter courses could be considered. Patients receiving Levaquin treatment should be warned about a potentially lethal risk to the aorta. The U.S. Centers for Disease Control and Prevention (CDC) say overprescribing is a widespread problem, and warn up to 50 percent of these prescriptions may be “inappropriate.”

photo of attorney Joe Lyon
A Voice for Those who have suffered 

Why are these cases important?

By taking the initiative and filing drug injury lawsuits, plaintiffs can receive proper compensation and hold a corporation accountable for their negligent actions. Consumer safety depends largely on making sure companies operate within the law and within ethical boundaries.

CONTACT THE LYON FIRM TODAY

  • This field is for validation purposes and should be left unchanged.

Questions about Pharmaceutical Litigation

Do i have a case?

When drug makers and large corporations are negligent and produce dangerous products that lead to serious illness and injury, legal action can be necessary. In the current corporate environment, filing lawsuits is one of the only ways to keep drug companies from selling untested and dubious pharmaceuticals in the name of profit. Pharmaceutical litigation – through a lawsuit against a drug manufacturer- helps bring awareness to these companies as to the necessary changes that need to occur in order to keep people safe a healthy while taking a  certain drug. 

By taking the initiative and filing drug injury lawsuits, plaintiffs can receive proper compensation and hold a corporation accountable for their negligent actions. Consumer safety depends largely on making sure companies operate within the law and within ethical boundaries.

How does the drug label come into play?

In past litigation, it has been discovered that drug companies often delay adding serious side effects to a drug’s label due to concerns about the impact on the sales and marketing. If a drug carries more serious side effects, physicians and patients look for alternative treatments with less risk and the same or similar benefit.  As a result, there is a financial incentive not to strengthen the warning label.

However, the label is the source of information that physicians and patients rely upon when making these important health decisions.  There is no excuse for a company not to update its label when the science is sufficient to show an association with the medication.

How does this relate to the FDA?

Most experts would agree that the FDA is not designed nor does it have the resources to monitor every product through the post approval process once it has been granted clearance. Very simply, the volume of drugs that are presented for review is too demanding, so, while the FDA is a good initial step in the process, the responsibility of providing safe and effective pharmaceutical companies remains on the companies that profit from the sales.

While the pharmaceutical companies have yielded more influence over the review process, ultimately, the law is very clear that it is the company’s responsibility to run the appropriate tests, track the data, and to identify the side effects and then warn consumers and physicians adequately and in a timely manner. Government approval is not a shield for liability. The Failure to timely and sufficiently warn of side effects operates as the primary cause of action for pharmaceutical claims.

Most importantly, the FDA and the government do not provide for compensation when someone is injured by a pharmaceutical product.  The civil justice system provides the means for an individual harmed by a pharmaceutical product to obtain justice and recover for the losses suffered.

Without the civil justice system, companies would not be required to pay for the harm they cause, and the public tax system, in terms of Medicare and Medicaid, would have to absorb that loss. In other words, without pharmaceutical lawsuits, the tax payers would pay for corporate malfeasance and neglect.

What are some examples of Pharmaceutical Settlements?

The current opioid crisis is a good example of how over-prescribing medications can lead to a huge public health crisis. Pain medications have been a great tool for physicians in treating a wide variety of conditions, however, the abuse of prescribing and using pain medication has turned into one of biggest areas of pharmaceutical litigation today.

It is not only opioids that have been prescribed in huge numbers. Other drugs that have only been tested in short trials are released to the market each year and injure patients. A few examples of drug injury:

Testosterone: Low T clinics are under investigation after many patients receiving testosterone therapy have reported strokes and heart attacks. Experts say doctors may be pushing the therapy when not every aging man requires testosterone therapy.

AntibioticsAntibiotic injuries are being reported at record rates as the drugs are prescribed more than ever before. Drug resistance and drug injury rates are on the rise, concerning the medical community and consumer protection attorneys.

Diabetes Drug Injury: Severe side effects are being reported by diabetes patients taking Invokana and other diabetes medications. Amputations and gangrene cases have opened the eyes of many taking the drugs, and lawsuits have been filed on their behalf.

Drug Contamination: Valsartan and Losartan contamination cases have raised the risk of patient cancer. Drug companies have failed to control the production process and put consumers at unnecessary risk.

Opioid Painkiller Lawsuits: Purdue Pharma, Johnson & Johnson and other large drug companies are deep in pharmaceutical settlement talks many years after the beginning of the opioid addiction crisis. Thousands of Americans die each year in opioid-related overdose deaths, many of which begin with doctors over-prescribing pain medications.

Depo Provera: Confidential settlement from Pfizer to resolve all of the claims currently pending in the New Jersey State coordinated litigation. Joseph Lyon represented 13 females who suffered osteoporosis due to the failure of Pfizer to properly warn them and their physicians.

Seroquel: AstraZeneca resolved claims for $198 Million regarding claims that the company failed to warn about risks of diabetes and excessive weight gain. The Lyon Firm participated in this settlement and represented numerous claimants. In addition to the individual claims, Federal prosecutors and authorities from several U.S. states investigated whether AstraZeneca promoted Seroquel off-label, or for uses not approved by the U.S. Food and Drug Administration. The company announced a settlement of $520 million with the U.S. Justice Department over the matter.

Trasylol: Bayer resolved certain claims for $60 Million for patients who suffered heart failure and death as a result of the drug Trasylol.  Trasylol was a drug used to prevent excessive bleeding during heart surgery. The science unequivocally showed Trasylol can cause kidney damage, heart failure and strokes, and greatly increase patients’ risk of post-surgery death when compared to rival treatments.

In 2006, a study by Dr. Dennis Mangano was published in the New England Journal of Medicine concluding that the drug more than doubled the risk of renal failure.  After fourteen years on the market, Bayer suspended sales in November 2007. The Lyon Firm participated in this settlement.

Vioxx: Merck settled the outstanding Vioxx claims for $4.85 billion. The Lyon Firm participated in this settlement.  In 2004, after a study showed Vioxx doubled the risk of heart attacks and strokes, Merck pulled Vioxx from the market. The case was then litigated with 16 trial ultimately going to the jury for a decision. Merck prevailed in 11 of the 16 trials.

Despite the settlement, Merck has not admitted that that Vioxx caused injuries. Each claim under the settlement was analyzed under an protocol that weighed such factors as a user’s age, their length of use, and their health risks such as obesity or hypertension. The individual extraordinary payout for a heart attack case was capped at $600,000.

How are the cases handled?

Pharmaceutical litigation is a complex area of law that combines dense regulation, developing science, and multi-jurisdictional questions of law. Most cases involving claims of drug injury and pharmaceuticals become centralized in the federal multidistrict litigation process. Pharmaceutical litigation involving injury claims are not in most cases not class action lawsuits, but they are very similar.

Due to the volume of cases and number of similar issues, most pharmaceutical cases are handled through Multidistrict Litigation (MDL). The multidistrict litigation procedure is guided by the Judicial Panel for Multidistrict Litigation, where the case is centralized before one federal Judge for the purposes of pre-trial discovery.

The MDL process is appropriate where there are one or more common questions of fact in multiple cases pending in different federal district courts.  While there often are parallel state consolidated proceedings, the federal MDL process is generally supported by both Plaintiff and Defendants in these cases.

The MDL process allows for efficiency where there are millions of pages of documents, many expert witnesses across multiple disciplines from epidemiology, pharmacology, toxicology and the specific discipline for the relevant mechanism of injury.

Although 28 USC 1407 does not specify a specific number of cases required before the formation of an MDL is appropriate, the Judicial Panel for Multidistrict Litigation reviews the Motions and conducts a hearing to determine whether consolidation is ripe given the number and location of the pending cases.

What is an MDL?

Most people understand what a class action lawsuit is, and fewer are aware of what an MDL refers to. It is important for a claimant to know, however, that an MDL is not a class action, as the term is often misapplied in this context, and the original court (home or transferee jurisdiction) retains the authority to present the case at trial.

In most MDL settings, the case is resolved by way of settlement or a summary judgment motion on the questions of science (i.e., Daubert Motion). If either settlement or dismissal on Motion occurs, the case is not remanded to the originating court. If the case is not resolved at the MDL, then the case may be remanded to original jurisdiction for additional discovery on the case specifics and ultimately trial.

Our Victories

The Lyon Firm aggressively, professionally, and passionately advocates for injured individuals and families against companies due to a drug to obtain just compensation under the law. 

IN RE: VIOXX

Nationwide Consolidation in U.S. District Court, E. Dist. of LA. 

This pharmaceutical case involved claims that the blockbuster painkiller was causing heart attacks and strokes in consumers. The FDA ultimately recalled the medication. Merck settled the outstanding Vioxx claims for $4.85 billion following multiple trials in both state and federal courts. Joe Lyon was co-counsel in a number of individual claims that were successfully resolved in the federal MDL. The funds received for Lyon Firm clients helped several elderly clients with additional medical and home health care.

IN RE: TRASYLOL

Nationwide Consolidation in Civil Complex Litigation Center Philadelphia, PA. 

A pharmaceutical case involving claims that a popular surgical medication was causing kidney failure and death. The FDA recalled the medication in question, but not before thousands of patients died due to related complications. Bayer resolved certain claims for $60 Million for patients who suffered kidney failure and death as a result of using the drug Trasylol. Joseph Lyon represented a widow from Kentucky whose husband died due to kidney failure following the administration of Trasylol. The recovered funds assisted the surviving family members in resuming farming operations.